Fernando Caravaca-Fontán

Fernando Caravaca-Fontán

Auto-generated profile, based on publicly available information

Fernando Caravaca-Fontán

Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre , Madrid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
HHHiddo J L Heerspink
Hiddo J L Heerspink
TGTom Greene
Tom Greene
HTHocine Tighiouart
Hocine Tighiouart
RGRon T Gansevoort
Ron T Gansevoort
JCJosef Coresh
Josef Coresh
WKWilliam Keane
William Keane

17 June 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LILesley A. Inker
Lesley A. Inker
WCWillem Collier
Willem Collier
TGTom Greene
Tom Greene
SMShiyuan Miao
Shiyuan Miao
JCJuhi Chaudhari
Juhi Chaudhari
HHHiddo J. L. Heerspink
Hiddo J. L. Heerspink

5 November 2018 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
GJGema Maria Fernández Juárez
Gema Maria Fernández Juárez
JPJavier Villacorta Perez
Javier Villacorta Perez
FCFernando Caravaca-Fontán
Fernando Caravaca-Fontán
LQLuis F. Quintana
Luis F. Quintana
ASAmir Shabaka
Amir Shabaka
O(on behalf of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)
on behalf of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)
Background and objectives: Drug-induced acute interstitial nephritis represents an emerging cause of acute kidney disease, especially among polymedicated elderly patients. Although corticosteroids are frequently used, controversy exists about the timing of initiation, efficacy, safety, and duration of treatment. Design, setting, participants, & measurements: We performed a retrospective study of 182 patients with biopsy-proven drug-induced acute interstitial nephritis from 13 Spanish centers. Exposure was defined as the length of corticosteroid treatment. The main outcome was the level of serum creatinine at month 6, with respect to baseline values. Results: The most common offending agents were nonsteroidal anti-inflammatory drugs (27%). In 30% of patients, the offending drug could not be identified. The median time to suspected drug withdrawal was 11 days (interquartile range, 5–22). All patients presented with acute kidney disease and were treated with corticosteroids. The mean initial dose of prednisone was 0.8±0.2 mg/kg per day. High-dose corticosteroid treatment was maintained for 2 weeks (interquartile range, 1–4). After 6 months, the mean recovered GFR was 34±26 ml/min per 1.73 m2 and ten patients required maintenance dialysis. Use of high-dose corticosteroids for 3 weeks or treatment duration >8 weeks were not associated with better recovery of kidney function. In the multivariable analysis, delayed onset of steroid treatment (odds ratio, 1.02; 95% confidence interval, 1.0 to 1.04) and the presence of interstitial fibrosis of >50% on the kidney biopsy specimen (odds ratio, 8.7; 95% confidence interval, 2.7 to 27.4) were both associated with serum creatinine level at month 6 of >75%, with respect to baseline values. Conclusions: High-dose corticosteroid treatment for 3 weeks or prolonged treatment for >8 weeks were not associated with greater kidney function recovery in drug-induced acute interstitial nephritis. A delay in the initiation of corticosteroids resulted in worse recovery of kidney function.

1 October 2019 in Kidney International
Verified
Journal Article
Closed access
TCTeresa Cavero
Teresa Cavero
EAEmilia Arjona
Emilia Arjona
KSKarina Soto
Karina Soto
FCFernando Caravaca-Fontán
Fernando Caravaca-Fontán
CRCristina Rabasco
Cristina Rabasco
MPManuel Praga
Manuel Praga

19 August 2020 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
FCFernando Caravaca-Fontán
Fernando Caravaca-Fontán
Montserrat Díaz-EncarnaciónMontserrat Díaz-Encarnación
Montserrat Díaz-Encarnación
LLLaura Lucientes
Laura Lucientes
TCTeresa Cavero
Teresa Cavero
VCVirginia Cabello
Virginia Cabello
OGon behalf of the Spanish Group for the Study of Glomerular Diseases GLOSEN
on behalf of the Spanish Group for the Study of Glomerular Diseases GLOSEN
Background and objectives: C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components. Previous studies showed that treatment with corticosteroids plus mycophenolate mofetil (MMF) was associated with improved outcomes, although the genetic profile of these patients was not systematically analyzed. This study aims to analyze the main determinants of disease progression and response to this therapeutic regimen. Design, setting, participants, & measurements: We conducted a retrospective, multicenter, observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients diagnosed with C3 glomerulopathy (n=81) or dense deposit disease (n=16) between January 1995 and March 2018 were enrolled. Multivariable and propensity score matching analyses were used to evaluate the association of clinical and genetic factors with response to treatment with corticosteroids and MMF as measured by proportion of patients with disease remission and kidney survival (status free of kidney failure). Results: The study group comprised 97 patients (84% C3 glomerulopathy, 16% dense deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this treatment was associated with a higher rate of remission and lower probability of kidney failure (79% and 14%, respectively) compared with patients treated with other immunosuppressives (24% and 59%, respectively), or ecluzimab (33% and 67%, respectively), or conservative management (18% and 65%, respectively). The therapeutic superiority of corticosteroids plus MMF was observed both in patients with complement abnormalities and with autoantibodies. However, patients with pathogenic variants in complement genes only achieved partial remission, whereas complete remissions were common among patients with autoantibody-mediated forms. The main determinant of no remission was baseline proteinuria. Relapses occurred after treatment discontinuation in 33% of the patients who had achieved remission with corticosteroids plus MMF, and a longer treatment length of MMF was associated with a lower risk of relapse. Conclusions: The beneficial response to corticosteroids plus MMF treatment in C3 glomerulopathy appears independent of the pathogenic drivers analyzed in this study.

5 May 2020 in Nephron
Verified
Journal Article
Open access
PDF file
FCFernando Caravaca-Fontán
Fernando Caravaca-Fontán
LLLaura Lucientes
Laura Lucientes
TCTeresa Cavero
Teresa Cavero
MPManuel Praga
Manuel Praga
C3 glomerulopathy (C3G) is a clinicopathologic entity secondary to dysregulation of the alternative complement pathway in plasma and the glomerular microenvironment. The current consensus definition of C3G relies on immunofluorescence staining criteria. However, due to its high clinical variability, these criteria may not be accurate enough in some clinical scenarios. Thus, a new pathogenic classification based on a cluster analysis of clinical, histologic, and genetic data has recently been proposed, which could also help identify patients at higher risk of progression. Several pathogenic abnormalities in complement genes have been described, and the role of autoantibodies in the disease is increasingly recognized, but still the genotype-phenotype correlations in C3G are poorly understood. C3G may be diagnosed in both children and adults. The spectrum of clinical manifestations is wide, although one of the most common clinical presentations is proteinuria with relatively preserved kidney function. In order to standardize the evaluation of kidney biopsies from these patients, a histopathologic index was recently proposed, including both parameters of activity and chronicity. However, this index has not yet been validated in independent cohorts. Currently, no targeted therapies are available in clinical settings for the treatment of C3G, although several new molecules are under investigation. Treatment with corticosteroids plus mycophenolate mofetil has been shown to be associated with improved renal outcomes, as compared to other immunosuppressive regimens. Yet, the main determinants of treatment response with this regimen and the influence of the underlying pathogenic drivers have not been extensively studied. The therapeutic response to eculizumab, an anti-C5 monoclonal antibody, has been shown to be highly heterogeneous. Thus, its current clinical indication in C3G is restricted to rapidly progressive forms of the disease. To summarize, in recent years, several important advances have taken place in the understanding of C3G, but still further studies are warranted to elucidate the best therapeutic strategies that could improve prognosis of this entity.